Artificial Intelligence (AI) In Drug Discovery Market (By Type: Preclinical and Clinical Testing, Molecule Screening, Target Identification, De Novo Drug Design and Drug Optimization; By Application: Neurology, Infectious Disease, Oncology, Others; By Drug Type: Small Molecules, Large Molecules; By Offering: Software, Services; By Technology; By End User) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2022-2030


The global artificial intelligence (AI) in drug discovery market size was estimated at USD 1153.6 million in 2021 and is projected to hit around USD 11,914 million by 2030, registering growth at a CAGR of 29.62% from 2022 to 2030.

Artificial Intelligence In Drug Discovery Market Size 2022 to 2030

Key Takeaways:

  • By therapeutic area, U.S. AI in drug discovery market was valued at USD 483.7 million in 2021.
  • By therapeutic area, the oncology segment accounted revenue share of 21% in 2021 and the infectious diseases segment is projected to grow at a fastest CAGR from 2022 to 2030.
  • Based on application, the drug optimization and repurposing segment has garnered revenue share of around 51% in 2021 and the preclinical testing segment is growing faster.
  • North America accounted largest market share 56% in 2021.
  • The APAC market is projected to grow at a notable CAGR of 21.1% from 2022 to 2030.

Man-made brainpower is a subfield of software engineering worried about recreating wise way of behaving. It permits PCs to think and do different exercises, like individuals and creatures, while gaining from their errors. Man-made brainpower is much of the time a calculation intended to permit a machine to achieve undertakings really while making little blunders. It applies profound learning and AI techniques to exemplified information while performing different exercises.

Artificial intelligence reasoning has significant ramifications in drug research since it can distinguish sicknesses, foster illness cures, and guess which creature infections will advance. Man-made consciousness has been displayed to further develop R&D in drug improvement, helping scientists in the revelation of ongoing disease treatments. Prescription disclosure and improvement are techniques in medication, pharmacology, and biotechnology for making, planning, and getting a medication by finding a natural objective, like a compound, protein, quality, or receptor. Drugs were recently found by recognizing the dynamic part in customary treatments. Consequently, drug disclosure is the underlying stage in tracking down conceivable creative prescriptions and their helpful purposes.

New medication standards are being created to survey bioavailability, adequacy, power, and harmfulness. Man-made consciousness has been broadly utilized in the medical care business, especially in the revelation of new meds. This can find remedial targets and assumes a significant part in finding, creating, recognizing, and screening little mixtures quicker than expected. Besides, because of the upsides of taking on these cutting edge methods over customary cycles, the market is anticipated to increase at an outstanding rate all through the gauge period. Moreover, the market is being moved basically by an expansion in the quantity of modern collusions and organizations. Besides, computerized reasoning limits the expense and time spent taking drugs research, which supports market development.

Growth Factors

The expanded craving for diminishing the absolute time expected for the medication disclosure cycle would upgrade the interest for man-made reasoning (AI) in drug revelation, impelling the market's development pace considerably more. Creature models regularly require three to five years to find and upgrade compounds before they are assessed in people, however AI-controlled new companies might reveal and construct novel medications in days or months. Moreover, rising medical care spending limit and progressions in medical care foundation would be significant drivers of market extension. In view of its broad utilization by numerous associations for the distinguishing proof and screening of current medications utilized in the treatment of COVID-19, the Coronavirus pestilence helped the development of man-made reasoning in the medication advancement area. Artificial intelligence has been viewed as useful in tracking down dynamic mixtures for the anticipation of SARS-CoV, HIV, SARS-CoV-2, flu infection, and other infections.

During the pandemic, economies all over the planet depended on man-made brainpower based prescription revelation as opposed to customary immunization location processes, which require a long time to create and are similarly expensive, adding to the development of computerized reasoning (AI) in the medication disclosure market. The expanded utilization of man-made reasoning (AI) to effectively explore drug activity will drive up interest for man-made consciousness (AI) in the medication improvement industry. Moreover, the reduction in the expense of medication disclosure would be a critical component influencing the development pace of the man-made reasoning (AI) in drug revelation market. Another significant viewpoint adding to showcase improvement is mechanical progression. Fast urbanization and rising extra cash levels in arising and laid out countries will affect the development pace of man-made consciousness (AI) in the medication revelation business.

Moreover, the expansion in R&D exercises, as well as the rising use of cloud-based administrations and applications, would give worthwhile possibilities for the man-made brainpower in drug disclosure market extension. The rising interest from arising nations and the extension of biotechnology areas would drive the AI in drug revelation market's development rate from here on out.

Report Scope of the Artificial Intelligence (AI) In Drug Discovery Market

Report Coverage Details
Market Size by 2030 USD 11,914 Million
Growth Rate from 2022 to 2030

CAGR of 29.62%

North America Market Share in 2021 56%
Drug Optimization and Repurposing Segment Market Share in 2021 51%
Base Year 2021
Forecast Period 2022 to 2030
Segments Covered Type, Application, Drug Type, Offering, Technology, End User, Geography
Companies Mentioned

NVIDIA CORPORATION, Microsoft Corporation, INSILICO MEDICINE INC., Schrödinger, EXSCIENTIA, Cloud Pharmaceuticals, TOMWISE, INC


Type Insights

The preclinical and clinical testing portion held the biggest market by type in 2021, attributable to an expansion in the quantity of coordinated efforts between drug firms and AI suppliers for clinical and preclinical testing. Preclinical preliminaries are a phase of examination that starts before clinical preliminaries and gathers iterative testing, significant plausibility, and medication security information for drug improvement. Preclinical investigations require the utilization of examination instruments to stick to a severe logical norm of medication research and to recognize further developed helpful possibility for clinical preliminaries. As a result of the expanded execution of AI for De novo research, the De Novo drug plan and medication streamlining class is supposed to extend at the speediest rate over the projection period. The AI innovation region is additionally partitioned into profound learning and regulated learning. Other AI innovations incorporate support learning, unaided learning, and others.

Profound learning represented the best piece of the pie in 2021, and it is additionally anticipated to extend at the quickest Compound yearly development rate over the estimate period. Profound learning helps with the predictable administration of information, saves time, diminishes the probability of mix-ups in the medication improvement process, and limits the weight for end clients, which are a portion of the significant viewpoints driving the market extension of this class.

Technology Insights

In 2021, the AI area held the best portion of the overall market and is anticipated to extend at the quickest Compound annual growth rate during the estimate time frame. Profound learning, administered learning, support learning, solo learning, and other AI innovations are partitioned into the AI innovation segment. Profound learning represented the best piece of the pie in 2021, and it is additionally anticipated to extend at the quickest Compound yearly development over the figure period.

In 2021, the AI area held the best portion of the overall market and is anticipated to extend at the quickest CAGR during the conjecture time frame. The high utilization of AI innovation among CRO, drug, and biotechnology organizations, as well as the limit of these advancements to separate experiences from informational collections, which supports the medication improvement process, are a portion of the drivers driving this section's market development.

Application Insights

The AI in drug disclosure market is partitioned into five applications: neurodegenerative problems, immuno-oncology, cardiovascular sicknesses, metabolic diseases, and others. Because of the rising requirement for viable malignant growth medicines, the immuno-oncology classification will represent the most noteworthy portion of the market in 2021. During the projection time frame, the neurodegenerative problems area is supposed to have the best accumulate yearly development rate. The significance of AI in resolving momentum issues in neurological medication advancement, as well as essential collusions between drug firms and arrangement suppliers, are significant drivers driving the portion's quick ascent.

 The AI in drug revelation market is separated into five applications: neurodegenerative problems, immuno-oncology, cardiovascular sicknesses, metabolic diseases, and others. The quickest developing application region in this market is neurodegenerative problems. The limit of AI to foster medicines for troublesome problems, as well as market members' focus on conveying AI-based stages for neurological sicknesses, are answerable for the fragment's quick ascent. Falsely shrewd PC frameworks are broadly utilized in clinical examination. Normal purposes incorporate patient conclusion, start to finish drug revelation and improvement, expanding doctor patient correspondence, deciphering clinical records like medicines, and remotely treating patients. While PC frameworks every now and again go about responsibilities more successfully than individuals, best in class PC calculations have recently accomplished exactnesses tantamount to human experts in the field of clinical sciences. Some accept it may involve time until people are completely displaced in certain region in the clinical sciences. The objective of this paper is to separate publicity from truth by talking about how computerized reasoning is changing the scene of clinical science.

End user Insights

Drug and biotechnology firms held the best extent of the overall AI in drug disclosure market. The AI in drug disclosure market is partitioned into drug and biotechnology firms, contract research associations, research focuses, and college and government organizations. In 2021, drug and biotechnology firms held the greatest piece of the pie of AI in the medication revelation industry, while research focuses and college and government foundations are supposed to develop at the quickest rate over the conjecture period. This end-client class is growing because of the appeal for AI-based arrangements that make the whole medication disclosure process additional time and financially savvy.

Research focuses and scholarly and government foundations, then again, are anticipated to develop at the quickest rate all through the projection period. The developing interest for AI-based innovations to accelerate and decrease the expense of medication improvement is a huge development factor for the drug and biotechnology end-client industry.

Geography Insights

North America is anticipated to represent the best portion of the overall AI in drug revelation market in 2021, as well as the most elevated build yearly development rate during the conjecture time frame. North America, which incorporates Canada, Mexico, and the United States, is the biggest market for AI in drug revelation. These nations were among quick to involve AI innovation in drug disclosure and improvement. The presence of huge laid out organizations, a deeply grounded drug and biotechnology area, and a solid accentuation on Research and improvement exercises and significant speculation are a portion of the essential reasons liable for this market's large offer and quick development rate.

Asia-Pacific is anticipated to develop essentially from 2022 to 2030 because of expanded interest in innovative work exercises nearby. The country part of the examination likewise incorporates individual market influencing components and changes in regulation in the market that influence present and future market patterns. Downstream and upstream worth chain investigation, mechanical patterns and doorman's five powers examination, and contextual analyses are a portion of the information focuses used to expect the market situation for various countries. Furthermore, the presence and accessibility of worldwide brands, as well as the issues they face attributable to huge or scant contest from nearby and homegrown brands, are considered while giving estimate examination of country information.

Key market developments

  • Chief.AI, the AI working stage, reported the send off of a pay-more only as costs arise AI stage for drug improvement in July 2021. This stage empowers SMEs to get reasonable admittance to state of the art innovation, diminishing the hit-or-miss nature of medication advancement and recognizing advancement medicines with sped up and accuracy.
  • Beginning Therapeutics and Genentech declared a multi-target drug improvement understanding in October 2020, using Genesis' chart AI capacities to reveal remedial contender for various diseases.

Key market players

  • NVIDIA CORPORATION
  • Microsoft Corporation
  • INSILICO MEDICINE INC.
  • Schrödinger
  • EXSCIENTIA
  • Cloud Pharmaceuticals
  • CLOUD PHARMACEUTICAL
  • TOMWISE, INC

Segments covered in the report

(Note*: We offer report based on sub segments as well. Kindly, let us know if you are interested)

By Type

  • Preclinical and Clinical Testing
  • Molecule Screening
  • Target Identification
  • De Novo Drug Design and Drug Optimization

By Application

  • Neurology
  • Infectious Disease
  • Oncology
  • Others

By Drug Type    

  • Small Molecules
  • Large Molecules

By Offering        

  • Software
  • Services

By Technology 

  • Machine Learning
    • Deep Learning
    • Supervised Learning
    • Reinforcement Learning
    • Unsupervised Learning
    • Other Machine Learning Technologies
  • Other Technologies

By End User

  • Pharmaceutical & Biotechnology Companies
  • Contract Research Organizations
  • Academics & Research
  • Others

 By Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Malaysia
    • Philippines
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (MEA)
    • GCC
    • North Africa
    • South Africa
    • Rest of the Middle East & Africa

Frequently Asked Questions

What is the current size of artificial intelligence (AI) in drug discovery market?
The global artificial intelligence (AI) in drug discovery market size was accounted at USD 1153.6 million in 2021 and it is expected to reach around USD 11,914 million by 2030.
The global artificial intelligence (AI) in drug discovery market is poised to grow at a CAGR of 29.62% from 2022 to 2030.
The major players operating in the artificial intelligence (AI) in drug discovery market are NVIDIA CORPORATION, Microsoft Corporation, INSILICO MEDICINE INC., Schrödinger, EXSCIENTIA, Cloud Pharmaceuticals, TOMWISE, INC
Rising medical services spending limit and headways in medical care framework would be significant drivers of market extension
North America region will lead the global artificial intelligence (AI) in drug discovery market during the forecast period 2022 to 2030.
  • Report Code:1875
  • Category:Healthcare
  • No. of Pages:150+
  • Format:PDF/PPT/Excel
  • Status:Published

PROCEED TO BUY

   USD 4500
   USD 7000
   USD 9000

ASK FOR SAMPLE

No cookie-cutter, only authentic analysis – take the 1st step to become an Precedence Research client

Get a Sample